A randomized double blind studyh of Ruxolitinib or placebo in combination with Regorafenib in subjects with relapsed or refractory metastatic colorectal cancer.
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Incyte Corporation
Start Date
October 1, 2014
End Date
September 30, 2019
Administered By
Duke Cancer Institute
Awarded By
Incyte Corporation
Start Date
October 1, 2014
End Date
September 30, 2019